SQZB (SQZ Biotechnologies Co) Total Equity: $1.88 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SQZB SQZ Biotechnologies Co SQZB
12 GF Score
Price $0.02
View Full Analysis

What is SQZ Biotechnologies Co Total Equity?

SQZ Biotechnologies Co SQZB 12 Total Equity is $1.88 Mil as of Sep. 2023. GuruFocus rates SQZB with a GF Score™ of 12/100.

SQZ Biotechnologies Co's total equity for the quarter that ended in Sep. 2023 was $1.88 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

SQZ Biotechnologies Co Total Equity Historical Data

* Premium members only.

The historical data trend for SQZ Biotechnologies Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SQZ Biotechnologies Co Total Equity Chart

SQZ Biotechnologies Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Total Equity
-43.54 -73.52 127.20 123.98 57.15

SQZ Biotechnologies Co Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.57 57.15 40.16 24.54 1.88
SQZB
12GF Score
SQZ Biotechnologies Co SQZB
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SQZ Biotechnologies Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

SQZ Biotechnologies Co's Total Equity for the fiscal year that ended in Dec. 2022 is calculated as

Total Equity=Total Assets(Q: Dec. 2022 )-Total Liabilities(Q: Dec. 2022 )
=99.9-42.752
=57.15

SQZ Biotechnologies Co's Total Equity for the quarter that ended in Sep. 2023 is calculated as

Total Equity=Total Assets(Q: Sep. 2023 )-Total Liabilities(Q: Sep. 2023 )
=29.788-27.907
=1.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $1.88 Mil mean?
SQZ Biotechnologies Co (SQZB) has a Total Equity of $1.88 Mil as of Sep. 2023. The total amount of equity as record on a company's balance sheet. View historical data for SQZ Biotechnologies Co and its competitors.
Is SQZ Biotechnologies Co's Total Equity too high?
SQZ Biotechnologies Co's current Total Equity is $1.88 Mil. Overall, SQZ Biotechnologies Co has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SQZ Biotechnologies Co's Total Equity compare to AGTX and ISCO?
SQZ Biotechnologies Co's Total Equity of $1.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for SQZ Biotechnologies Co and its competitors. SQZ Biotechnologies Co's current Total Equity is $1.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SQZ Biotechnologies Co stock overvalued right now?
SQZ Biotechnologies Co (SQZB) has a current Total Equity of $1.88 Mil. The current Total Equity is $1.88 Mil. SQZ Biotechnologies Co's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For SQZ Biotechnologies Co (SQZB), the current Total Equity is $1.88 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SQZ Biotechnologies Co Business Description

Address 200 Arsenal Yards Boulevard, Suite 210, Watertown, MA, USA, 02472
SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.
12GF Score

Get the complete analysis for SQZB

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price